🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Matched placebo for test product, Duvakitug

    Sanofi-aventis Healthcare Pty Ltd

    Immune system disseases

    phase 3 small molecule active

    1 trial

  2. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  3. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial

  4. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial

  5. Matches test film-coated tablets, Wakix 4.5 mg film-coated tablets, Wakix 18 mg film-coated tablets

    Bioprojet Pharma

    Narcolepsy

    phase 3 small molecule active

    1 trial

  6. Matching Placebo for Piclidenoson, Piclidenoson

    Can-Fite BioPharma

    Plaque psoriasis

    phase 3 small molecule active

    1 trial

  7. Matching placebo MGL-3196 60 mg film-coated tablet, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 100 mg film-coated tablet., MGL-3196 60 mg oral, MGL-3196 100 mg oral, MGL-3196 80 mg oral

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  8. Matching placebo for BAY 597939 2.5 mg filmcoated tablets, Rivaroxaban 2.5 mg

    The George Institute

    Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.

    phase 3 small molecule active

    1 trial

  9. Matching placebo for Tezepelumab solution for injection, TEZEPELUMAB

    AstraZeneca AB

    Severe Uncontrolled Asthma Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that asthma attacks are still occurring despite the use of other available treatments

    phase 3 small molecule active

    1 trial

  10. Mavorixafor, Mavorixafor Placebo Capsules

    X4 Pharmaceuticals, Inc

    Neutropenias

    phase 3 small molecule active

    1 trial

  11. Mavorixafor, Placebo to Test IMP

    X4 Pharmaceuticals, Inc

    WHIM Syndrome

    phase 3 small molecule active

    1 trial

  12. Medium-dosage COVID-19 Vaccine,Inactivated

    Sinovac Research and Development Co.,

    COVID-19

    phase 3 mab terminated

    1 trial

  13. Meningococcal vaccine GSK134612

    GlaxoSmithKline

    Infections, Meningococcal

    phase 3 mab completed

    2 trials

  14. Metalyse 5 000 units (25 mg) powder for solution for injection

    Pari Pharma GmbH

    Adult patients with a LVOS with large core within 9 hours of symptoms onset or last seen well, or with a diffusion weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch in case of unknown onset.

    phase 3 small molecule active

    1 trial

  15. Metalyse 5 000 units (25 mg) powder for solution for injection

    Boehringer Ingelheim

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  16. Methadone (100% dose)

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 3 small molecule active

    1 trial

  17. Methylprednisolon acis 250 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Ocrevus 300 mg concentrate for solution for infusion, Gilenya 0.25 mg hard capsules, Placebo for FINGOLIMOD, Placebo for Ocrelizumab, Gilenya 0.25 mg hard capsules, Reisetabletten AL Dimenhydrinat 50 mg pro Tablette, Methylprednisolon acis 1000 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules

    Hoffmann-La Roche

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  18. Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Diphenhydramine Hydrochloride Tablets 50 mg

    Hoffmann-La Roche

    Progressive multiple sclerosis (PMS)

    phase 3 small molecule active

    1 trial

  19. Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg

    Hoffmann-La Roche

    Multiple sclerosis (MS)

    phase 3 small molecule active

    1 trial

  20. Methylprednisolone Aceponate Cream, Advantan 0.1% cream, Vehicle to Methylprednisolone Aceponate Cream

    Alphapharm Pty Ltd

    Mild to moderate atopic dermatitis

    phase 3 small molecule active

    1 trial

  21. Mexiletine granules for prolonged-release oral suspension 333 mg, Mexiletine granules for prolonged-release oral suspension 167 mg, Mexiletine granules for prolonged-release oral suspension 500 mg

    Lupin Europe GmbH

    Myotonic Dystrophy type 1 and type 2 (DM1/DM2)

    phase 3 small molecule active

    1 trial

  22. Mezagitamab, Mezagitamab placebo-matching injection administered SC

    Takeda

    IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Berger's disease)

    phase 3 small molecule active

    1 trial

  23. Micofenolato de mofetil Generis 250 mg Cápsulas, Inflectra 100 mg powder for concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Gemcitabine 100 mg/ml Concentrate for Solution for Infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Oxaliplatine Accord 5 mg/ml concentraat voor oplossing voor infusie

    AstraZeneca AB

    Advanced Biliary Tract Cancers

    phase 3 small molecule active

    1 trial

  24. Microcrystalline cellulose, Sodium Chloride, Magnesium Stearate, MK-0616

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources